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Abstract. The terminally differentiated adult cardiac myo-
cyte cannot undergo cellular division. Growth of the heart
in response to chronic hemodynamic overload therefore
occurs through hypertrophy of the myocytes. The adapta-
tion of the myocyte during hypertrophy not only involves an
increase in cell size but also results in a change in pheno-
type through modi~cation of the pattern of gene expres-
sion. From in vitro studies, it can be learned that agonists
like angiotensin-II, endothelin-1, cardiotrophin, basic
~broblast growth factor, insulin-like growth factor-I, or
stimulation with the a1-adrenergic agonist phenylephrine
can induce hypertrophy. In vivo studies suggest that espe-
cially angiotensin-II and endothelin-1 play a prominent role
in induction of hypertrophy during overload. These agonists
couple to classical seven-transmembrane spanning domain
(serpentine) receptors, signaling through activation of the
phosphoinositide pathway. This leads to generation of 1,2-
diacylglycerol and activation of protein kinase C. Surpris-
ingly, however, these agonists were also shown to activate
the mitogen-activated kinase (MAPK) pathway that is typi-
cally activated by (growth factor) receptors harboring (in-
trinsic) tyrosine kinase activity. Increased mechanical
forces exerted on the heart during overload also induce
hypertrophy, partly through autocrine and paracrine factors
such as angiotensin-II and/or endothelin-1. However, direct
stimulation of MAPK pathways by stretch might also be
exerted through cross-talk with an activated integrin-focal
adhesion kinase pathway. Activated MAPK partly translo-
cates to the nucleus, where phosphorylation processes are
initiated that lead to altered transcription factor activity.
Some transcription factors involved in expression regula-
tion in the hypertrophic myocyte have now been implied,
and knowledge concerning genetic cis-acting elements that
are involved is also increasing. However, the complexity and
interplay of different (and possibly still unknown) signaling
pathways do not yet warrant a complete picture regarding
the mechanism of in vivo hypertrophy development during
overload.
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In response to chronically increased workload, a com-
pensatory  mechanism in the heart is activated that
results in an increase of the mass of the ventricular
tissue. Ventricular myocytes are terminally differenti-
ated cells that cannot undergo cell division at large.
Thus, the increase of ventricular muscle tissue under
this condition is accomplished by hypertrophy, i.e., an
increase in size of individual myocytes.
Enlargement of cardiomyocytes is accompanied by
a change in gene expression that results in alteration
of the cardiac phenotype during hypertrophy. Some of
these changes can be seen as a positive adaptation, e.g.,
induction of atrial natriuretic factor (ANF) or (in ro-
dents) upregulation of b-myosin heavy chain (b-MHC)
expression. On the other hand, detrimental modi~cat-
ion of  gene expression also occurs.  In this respect,
downregulation of the expression of the genes encod-
ing, e.g., the sarcoplasmic reticulum Ca21–ATPase
(SERCA2 gene) and the b-adrenergic receptor (b-AR)
is thought to be important for the inevitable physi-
ological outcome of prolonged stimulation of the hyper-
trophic process, namely, heart failure [1].
Many agents have been implicated in the regulation
of the growth of the heart, including hormones like
angiotensin-II (AngII) and endothelin-1 (ET-1), a1-ad-
renergic neurotransmitters (e.g., the a1-agonist
phenylephrine, PHE, reviewed in [2]), interleukin-like
agents such as cardiotrophin-1 (CT-1) [3], several
growth factors [2,4,5], and as yet unidenti~ed factors
that mediate a direct response to increased mechanical
forces. Some of these factors have been shown to be
involved in hypertrophy induction in vivo. However,
interpretation of results from in vivo studies is ham-
pered by the possible simultaneous involvement of dif-
ferent factors as well as different cell types such as
cardiomyocytes, cardiac ~broblasts, and endothelial
cells. Furthermore, detailed analysis of the complex
and rapid activation of signaling pathways is virtually
impossible in the intact heart due to the presence of
different cell types. Therefore, the main evidence for
the involvement of the factors mentioned above in in-
duction of hypertrophy comes from in vitro models.
The most commonly employed in vitro model system is
that of short-term cultured neonatal rat cardiac myo-
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cytes. These cells respond to hypertrophic agonists by
an increase in protein synthesis, cell size, organization
of contractile proteins, and changes in gene expression
that are reminiscent of in vivo hypertrophy. In cul-
tured cardiac myocytes, it was furthermore shown that
diverse signal  transduction pathways are activated,
through which an extracellular signal is transmitted
from the receptor(s) to the nucleus via kinase cascades.
This article focuses on the way in which cardiac
myocytes sense and respond to the extracellular and
intracellular signals that ensue from enhanced demand
for work. Questions that will be addressed in this re-
spect are, e.g., which changes occur in cardiac pheno-
type during hypertrophy and failure, which agonists
can be implicated in signaling, which signal transduc-
tion pathways are activated, and how this activation
is transmitted to the genetic machinery that dictates
cardiac phenotypic changes during hypertrophy/fail-
ure.
Hypertrophy and Heart Failure
Prolonged hemodynamic overload of the heart, e.g., by
infarction, hypertension, or volume or pressure over-
load, ultimately leads to hypertrophy of the left ven-
tricular wall. This hypertrophic process involves signal
transduction (described below) that leads to rapid in-
duction of transcription factors (immediate early
genes). At a later stage, contractile (e.g., myosin light
chain-2, skeletal a-actin, and in rodents b-MHC) as well
as noncontractile protein genes (e.g., ANF) are in-
duced, not only resulting in growth of the cardiomyo-
cyte but also leading to changes in the contractile func-
tion of the cardiomyocyte [1,6]. These changes can be
judged to be a positive adaptation, allowing the heart
to maintain a normal cardiac output under the overload
conditions. Thus, the initial outcome is compensatory
growth of the heart by 1) increased myocyte cell-size,
with a well-developed contractile apparatus, 2) reex-
pression of the potent vasodilator (fetal) ANF gene in
the ventricular tissue that is bene~cial during hemody-
namic overload, and 3) improved economy of contrac-
tion by reexpression of the (fetal) b-MHC isoform (in
rodents) that exhibits a lower velocity of ATP cycling
and thus dissipates less ATP in the form of heat gen-
eration.
In contrast to the compensatory hypertrophic
phase, heart failure ensues during a second decompen-
satory phase. Although the exact “point of no return”
is still unknown, decompensation occurs when the hy-
pertrophic adaptation of the heart to an increased de-
mand for volume or pressure work does not lead to
alleviation of the workload. In this case, the continu-
ation of hypertrophic stimulation induces severe al-
terations in gene expression. These lead to diminished
capacity of the heart to perform work and thus to sup-
ply all tissues with enough oxygen and nutrients to
sustain (active) life [7]. The changes in gene expression
that are initiated in the hypertrophic phase lead not
only to altered architecture of the muscle (remodeling
accompanied by ~brosis) but also to catecholamine de-
sensitization (b-AR downregulation) and to deteriora-
tion of contractile properties. The latter phenomenon
may partly be explained by changes in expression of
Ca21-handling proteins, e.g., decreased expression of
the SERCA2 gene resulting in decreased velocity of
Ca21 uptake in the sarcoplasmic reticulum (SR) (i.e.,
decreased velocity of relaxation) and also leading to
lower SR ~lling, with Ca21 giving rise to reduced con-
tractility [8].
Changes in cardiac phenotype during hypertrophy
and heart failure will be depicted in more detail below.
Cardiac Phenotype in Hypertrophy
and Failure
Initial studies  regarding  gene-expression  regulation
during hypertrophy and failure were performed in ex-
perimental animal models. In the last years, however,
more and more data are derived from human, mainly
end-stage heart failure tissue, largely con~rming ob-
servations in the experimental models. Changes in
gene expression during hypertrophy and failure of con-
tractile proteins, membrane proteins, enzymes in-
volved in energy metabolism, proteins involved in sig-
nal transduction, and hormones are summarized in
table 1 [9–26]. The plethora of phenotypic changes that
occur during development of hypertrophy suggests
that the functional outcome for heart function will be
complex. Changes in gene expression that relate to
Ca21 handling are discussed below in more detail.
The activity of the SR Ca21 pump is decreased during
hypertrophy, leading to reduced velocity of relaxation.
The increased expression of the Na1–Ca21 exchanger
might be a compensatory mechanism to the reduced SR
function to increase the velocity of Ca21 clearance from
the cytoplasm. On the other hand, the increased expres-
sion of the Na1–Ca21 exchanger suggests that inward
Ca21 transport (by reversed Na1–Ca21 exchange) is en-
hanced after excitation of the myocyte, suggesting that
this is a compensatory adaptation to the decreased SR
~lling with Ca21 that is brought about by decreased SR
Ca21-pump activity. The observation that the expres-
sion of the SR (ryanodine-receptor) Ca21 release chan-
nel expression is decreased during heart failure fur-
thermore shows that the involvement of the SR in Ca21
movement during contraction/relaxation is decreased
at several functional levels.
The activity of the SR Ca21 pump is governed by a
regulator protein, phospholamban. This protein, in its
unphosphorylated state,  inhibits  Ca21-pump activity
by association with the SR Ca21 pump. The downregu-
lation of phospholamban expression during hypertro-
phy that is associated with decreased SR Ca21-pump
expression might therefore be a compensatory mecha-
nism. Furthermore, the inhibitory action of phospho-
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lamban is overcome through phosphorylation by pro-
tein  kinase A (PKA), coupled to the b-AR through
adenylate cyclase. Therefore, downregulation of phos-
pholamban under conditions where the b-adrenergic
receptor is decreased and the inhibitory Gi protein (in-
hibition of adenylate cyclase) is increased might also
serve a compensatory goal.
Taken together, severe impairment of Ca21 handling
in the hypertrophied/failing heart can be attributed to
altered expression of Ca21-handling proteins, despite
several compensatory changes that exist as well.
Factors Involved in Induction
of Hypertrophy
Most studies concerning the ability of single agonists
such as hormones, growth factors, and neurotransmit-
ter  analogues  to  induce  cardiomyocyte hypertrophy
have been performed in vitro using cultured ventricu-
lar myocytes. The criteria used in these studies to
judge whether an agonist can induce hypertrophy in
vitro are very diverse. These criteria range from true
hypertrophy (increased cell size, protein content, and
development of a well-ordered contractile apparatus)
to separate processes that are thought to be indispen-
sable for or to accompany development of hypertrophy,
such  as expression of immediate  early genes (c-fos,
c-myc, c-jun, and EGR-1), reexpression of ANF in ven-
tricular cells, increased myosin light chain-2 (MLC-2)
expression, or SERCA2 downregulation. However, we
must be aware that development of a single hypertro-
phy-associated process in vitro might not be typical for
the entire hypertrophy process seen in vivo. Thyroid
hormone, for example, activates a form of hypertrophy
that is accompanied by increased SERCA2 expression
[27]. Furthermore, other factors may activate only a
limited number of processes that accompany hypertro-
phy—e.g., ATP, which activates the immediate early
gene expression program but does not increase protein
synthesis [28]. Lastly, it is now becoming apparent that
ANF expression is not always a good marker for the
induction of hypertrophy [29]. This ~nding shows that
we have to be cautious in the extrapolation of in vitro
results to a possible in vivo hypertrophic capacity of
agents under study.
Results from in vitro studies indicate that an as-
tounding number of different factors can induce (as-
Table 1. Genomic expression in heart tissue during hypertrophy and failure
Subcellular localization and mRNA- and/or protein- Hypertrophy or
functional protein expression failure (species)
Contractile proteins
Myosin heavy-chain Isoform shifta Hypertrophy (h&nh)
Myosin light-chain ↑ Hypertrophy (h&nh)
Actin Isoform shift Hypertrophy (h&nh)
Troponin T Isoform shift End-stage failure (h)
Membrane proteins
L-type Ca21 channel (SL) Controversial (↓) Failure (h)
Na1/K1 pump (SL) ↓ (Isoform speci~c) Failure (h&nh)
Na1/Ca21 exchanger (SL) ↑ Failure (h)
Voltage-gated K1 channel (SL) ↓ (Isoform-speci~c) Hypertrophy (nh)
Ca21 channel (SR)b ↓ End-stage failure (h)
Ca21 pump (SR) ↓c Hypertrophy (h&nh)
Phospholamban (SR) ↓ Hypertrophy (h&nh)
Energy metabolism
Creatine kinase ↓d Failure (h)
Signal transduction
Gs protein 5 Failure (h)
Gi protein ↓ Failure (h)
Protein kinase C ↓(Isoform speci~c) Failure (nh)
b-Adrenergic receptor ↓(Isoform speci~c) Failure (h&nh)
AngII receptor ↑ Hypertrophy (h&nh)
Others
Inducible nitric oxyde synthase ↑ Failure (h)
Transcription factor MEF-1 ↑ Hypertrophy (nh)
aIn human atrium only.
bRyanodine-sensitive Ca21-channel.
cSome controversy exists with regard to the correlation between mRNA level (decreased) and protein level (decreased or unchanged) [24–26].
dActivity measurement.
Note: The column Hypertrophy or failure (species) denotes the earliest point in time at which changes in expression were studied. Species relates
to human (h) heart tissue or nonhuman (nh, mainly rat) experimental models. Data were taken from [9], together with [10–23]. ↑ and ↓ denote
increased and decreased expression, respectively.
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pects of) hypertrophy. These agonists span the diverse
families of signal transduction pathways known at pre-
sent. Hypertrophy can be induced by agonist activa-
tion of seven membrane-spanning-domain (serpentine)
receptors that couple to phospholipase C activation, as
was shown for AngII (AT1 receptor) [30, 31], ET-1 (ET-
A receptor) [32], PHE (a1A-adrenergic receptor) [33],
and thrombin [2]. On the other hand, several growth
factor receptors were also shown to have some hyper-
trophic capacity in vitro. Among these are the recep-
tors for insulin-like growth factor-I (IGF-I) and basic
~broblast growth factor (bFGF) [2,4] that signal
through intrinsic receptor tyrosine kinase activity. A
further kinase pathway that was implicated in the in-
duction of hypertrophy involves cytokine-receptor sig-
naling, in the case of the cardiac myocyte activated by
cardiotrophin-1 (CT-1) [3].
All the stimuli mentioned above are of a neurohu-
moral nature.  It  is,  however, well  documented that
stretching of cardiac myocytes also leads to hypertro-
phy. It was subsequently shown that this stretch-in-
duced hypertrophy involves an autocrine and parac-
rine mechanism, namely, the release of AngII by
cardiac myocytes [34]. However, induction of hypertro-
phy by stretch is not totally inhibited by blockade of
AngII receptors [35], suggesting additional stimuli to
play a role in this process. A recent study indeed shows
that another hormone, ET-1, is secreted by stretched
cardiomyocytes [36]. ET-1 receptor blockade partly in-
hibited the increase in protein synthesis brought about
by stretch. ET-1 and AngII were furthermore shown
to synergistically activate the raf/MAPK pathway (de-
scribed below) [36] that mediates signal transduction
leading to hypertrophy. This ~nding suggests that me-
chanical overload of the cardiac myocyte leads to mul-
tifactorial induction of hypertrophy.
Changes in membrane stress (e.g., those that occur
during cyclic stretch of cardiomyocytes) are normally
sensed by integrins that convey an activation signal to
a focal adhesion kinase (FAK) [37]. Thus, even a fourth
class of signaling molecules might activate hypertro-
phy. However, this pathway has only been sparsely
studied in cardiac myocytes in a model of swelling-in-
duced activation, and evidence for involvement in
transmittal of mechanical forces in stretch-induced hy-
pertrophy is not yet available.
As mentioned above, the in vitro model of cultured
cardiomyocytes that is used in most of the studies with
regard to induction of hypertrophy circumvents the
possible interplay of different cell types through parac-
rine mechanisms. However, we must bear in mind that
the in vivo induction of hypertrophy will almost cer-
tainly involve several factors that may even sequen-
tially interact during hypertrophy/failure develop-
ment. A good example in this context is the corelease
of  ATP  with  the  adrenergic agonist  norepinephrine
from nerve endings. ATP alone, through P2 purinergic
receptors, can activate immediate early genes but does
not induce hypertrophy. However, the normal hyper-
trophic response to a1-adrenergic agonist is inhibited
in the presence of ATP [38]. This ~nding suggests that
identi~cation of all factors involved in in vivo induction
of hypertrophy will not be easy.
Nevertheless, some in vivo models of cardiac over-
load have already given insight into the identity of
factors that play a prominent role in hypertrophy in-
duction and heart failure. Experimental left ventricu-
lar (LV) infarction in rats by coronary artery ligation
leads to hypertrophy of remaining viable tissue, de-
creased contractility, and in the long run to decreased
survival due to heart failure. After infarction, myo-
cardial ET-1 levels are increased. Blocking the ET-1
receptor after infarction decreases contractility, indi-
cating that the ET-1 increase probably helps to main-
tain cardiac contractility [39]. Surprisingly, however,
despite the fact that ET-1 receptor blockade de-
creased contractility, this treatment also greatly im-
proved survival of rats with chronic heart failure [39].
Since the ET-1 antagonism was accompanied by pre-
vention of ventricular remodeling (hypertrophy), this
agonist seems to play a prominent role in develop-
ment of hypertrophy and failure during infarction-in-
duced cardiac overload. Furthermore, hypertrophy of
the heart provoked by hemodynamic overload after
aortic constriction also involves ET-1. In this model,
again it was shown that an ET-1 receptor antagonist
blocks development of cardiac hypertrophy [40]. How-
ever, ET-1 only seems to plays a role in the early
phases of pressure-overload hypertrophy since the ef-
fect of ET-1 receptor antagonism wears off after one
week.
Another factor that is now directly implicated in the
development of hypertrophy in vivo is AngII. After LV
myocardial infarction by ligation of the coronary artery
in rats, blockade of the AngII AT-1 receptor largely
prevented development of left ventricular hypertro-
phy [41]. Furthermore, in a model of spontaneously
hypertensive rats, the constantly exerted pressure
overload induces severe hypertrophy that gradually
develops with age. Administration of an AT-1 blocker
at an age when hypertrophy is already present not
only prevented further LV wall thickening but even led
to regression of hypertrophy [42]. Moreover, chronic
AngII infusion in rats led to increased LV mass, even
at  an  AngII dose where  bloodpressure  was not in-
creased [43].
These results indeed suggest that the development




Signal transduction in cardiac myocytes elicited by
agonists that are involved in induction of hypertrophy
has been a research topic for over a decade. Until a few
years ago, however, the main topic was signaling by
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seven-transmembrane spanning domain (serpentine)
receptors coupling to G-proteins. Over the last years,
another class of receptors has been implicated in hy-
pertrophy induction, namely, (growth factor) receptors
that harbor intrinsic tyrosine kinase activity. Even
more recent is the ~nding that yet another class of
receptors can be associated with hypertrophy, namely,
that of the cytokine receptors that signal through re-
ceptor-associated tyrosine kinases.
The description given above concerning activation
of three separate kinase pathways (serpentine-, recep-
tor tyrosine kinase-, and cytokine-receptor coupled) is
an intentional oversimpli~cation. As will be described
below, one of the most surprising discoveries of the last
years was the cross-talk between different kinase
pathways; serpentine- as well as cytokine-activated
signal transduction pathways cross-talk with the
MAPK pathway. This ~nding seems to make the
MAPK signaling pathway the converging point to
which signal transduction elicited by AngII, ET-1,
PHE and bFGF, IGF-I, and CT-1 is routed, all inducing
hypertrophy.
Below, we will describe the kinase pathways em-
ployed by these receptors in general, followed by a
description of signaling by speci~c hypertrophic
agonists. A general overview of the signal transduction
pathways is also given in ~gure 1.
Signal transduction in general
Serpentine receptors and  the phosphoinositide
pathway. Several seven-transmembrane-domain-
containing receptors have been detected in cardiac
myocytes. These include the phosphoinositide cycle-
coupled receptors for the hypertrophic agents AngII,
ET-1, and PHE [2]. Associated with these receptors
are heterotrimeric GTP-binding proteins, of which the
Ga subunit can bind GDP or GTP. Upon occupation, the
receptor catalyzes exchange of GDP for GTP on Ga.
This exchange activates the Ga protein and causes its
dissociation from Gbc. Both the Ga–GTP complex and
Gbc [44] can now regulate effector molecules. Signaling
by G-proteins is transient because of the intrinsic
GTPase of the Ga subunit.
Two classes of G-proteins are activated: Gq which
activates phospholipase C (PLC), and Gi, which inhibits
adenylate cyclase [45]. Gi activation results in de-
creased cAMP levels and decreased PKA activity. This
change may serve to relieve the inhibition of c-Raf
Fig. 1. General overview of signal transduction pathways activated by serpentine- growth factor and cytokine receptors. Activation of
serpentine receptors leads to inhibition of adenylate cyclase (AC) through the Gi GTP-binding protein, decreasing the activity of pro-
tein kinase A (PKA). This releases the inhibition that is brought about by raf phosphorylation. Through Gq, the same receptors acti-
vate phospholipase C (PLC), giving rise to protein kinase C (PKC) activation, leading to raf activation and MAPK activation. Growth
factor receptors directly activate the MAPK pathway. Cytokine receptors activate transcription regulation through STAT and are
thought to cross-talk to the MAPK pathway by a cytoplasmic adaptor protein Shc that might be involved in serpentine receptor signal-
ling as well. Further details with regard to signal transduction and downstream events are detailed in the text. Arrows (↓) denote
stimulatory pathways; ⊥ indicates an inhibition of the next enzyme; dashed arrows ( ) denote cross-talk between the MAPK path-
way and integrins (through FAK), serpentine-receptors, and cytokine receptors
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activation caused by phosphorylation by PKA, sug-
gesting that this is a ~rst point of cross-talk with the
MAPK pathway, as will be described below. Activation
of Gq is essential for PHE-induced hypertrophy and
was shown to lead to activation of the PLC b-isozyme
giving rise to  production of inositol (1,4,5)-trisphos-
phate (InsP3) and 1,2-DAG. In general, InsP3 releases
Ca21 from intracellular stores. However, in cardiomyo-
cytes this mechanism seems to be ablated by rapid
phosphorylation and dephosphorylation of InsP3 [46].
On the other hand, production of 1,2-DAG serves an
important role in signaling since it activates protein
kinase C.
The protein kinase C family of Ser/Thr kinases con-
sists of at least 12 members that can be divided into
three groups: classical cPKC isozymes, requiring Ca21
and 1,2-DAG for activation; novel nPKCs, requiring
only 1,2-DAG; and atypical aPKCs, for which the acti-
vation mechanism is still obscure. The presence of
cPKC-a, nPKC-d, nPKC-e, and aPKC-f has been well
documented in neonatal rat cardiac myocytes [45,47].
In contrast, only PKC-e together with a low amount of
PKC-d is present in adult cardiac myocytes. The pres-
ence of PKC-b in cardiac myocytes is still controver-
sial. Translocation of protein kinase C from the cyto-
plasm to a particulate (membrane) fraction is judged to
re_ect activation, as was the case for nPKC-d and -e
after stimulation with ET-1 or PHE [45,47]. Direct in-
volvement of PKC activation in the signal transduction
pathway that leads to (aspects of) hypertrophy was
shown in transfection studies employing constitutively
activated PKC isoforms [48]. Downstream signaling
from activated PKC towards gene regulation can
either involve direct phosphorylation of nuclear pro-
teins (histone, RNA- and DNA-polymerases) or cross-
talk to the MAPK pathway through phosphorylation
and activation of c-Raf (see below).
Tyrosine kinase receptors and the MAP kinase
pathway. Growth factor protein tyrosine kinase re-
ceptors activate the MAPK, also called extracellular-
signal regulated kinase (ERK) pathway (reviewed in
[45,49]). These receptors homodimerize upon binding
of the growth factor, whereupon autophosphorylation
of an intracellular tyrosine residue occurs. This now
serves as a docking site for adaptor proteins; the
growth factor receptor-binding protein Grb-2 is bound
to the receptor through its Src homology (SH2) do-
main, which is selective for phosphotyrosine-contain-
ing sequences. Another domain of Grb2, the SH3 do-
main, binds to SOS (son of sevenless). In this way, SOS,
a guanine nucleotide exchange factor (GEF), is
brought into the vicinity of membrane-bound ras, cata-
lyzing the exchange of GDP for GTP on ras. Mem-
brane-bound ras-GTP now binds to and activates raf
(MAPKKK), the ~rst enzyme of the MAP kinase path-
way. Moreover, this raf-kinase is a substrate for PKC
(stimulation) as well as for PKA (inhibition), indicating
that this is the enzyme that translates multiple signals
into one downstream phosphorylation event.
Several subfamilies of the MAP kinase pathways
have now been unraveled, all signaling through a
three-enzyme module. The (possibly physically joined)
basic components are the following: 1) The MAPK ki-
nase kinase MAPKKK (this is raf, as described above)
is also referred to as MEKK (i.e., MAPK/ERK kinase
kinase). This is a Ser/Thr protein kinase that becomes
activated by interaction with ras-GTP and probably
requires additional Tyr-phosphorylation for full activa-
tion. 2) MAPK kinase (MAPKK), the second compo-
nent of the module, is also referred to as MEK
(MAPK/ERK kinase). MAPKK is phosphorylated by
MAPKKK on Ser-XXX-Ser/Thr, where phosphoryla-
tion of both sites is required for full activation.
MAPKK itself is a so-called dual speci~city kinase,
since it is able to phosphorylate Ser/Thr as well as Tyr
residues. 3) The third component of the module gives
its name to the cascade: MAPK (or ERK) becomes
phosphorylated by MAPKK on Thr-X-Tyr, again re-
quiring dual phosphorylation for activation. MAPK it-
self is a so-called proline-directed Ser/Thr kinase that
phosphorylates target proteins on a Ser/Thr-Pro motif.
In mammalian cells, the best-studied MAPK super-
family members, which are also present in cardiac
myocytes, are ERK-1 (p44MAPK) and ERK-2 (p42MAPK),
where the phosphorylation domain is Thr-Glu-Tyr
[45,49]. These ERKs are activated by MEK1 and
MEK2, which were detected in cardiac myocytes as
well [5].
Several cytoplasmic substrates have been described
for MAPK. The cytoplasmic protein PHAS-I (phospho-
rylated heat- and acid-stable protein) is a target for
phosphorylation by MAPK, and complex formation be-
tween PHAS-I and eukaryotic initiation factor (eIF)-
4E protein is decreased upon PHAS-I phosphoryla-
tion. In this way, mRNA Cap-binding protein eIF-4E
becomes available  to initiate complex formation be-
tween ribosomes and mRNA, stimulating protein syn-
thesis. Another way in which the MAPK pathway can
regulate protein synthesis is by phosphorylation and
activation of p70S6K [50,51]. This S6 kinase, in its turn,
phosphorylates the S6 protein in the 40S small ribo-
somal subunit, thereby stimulating protein synthesis.
Phosphorylation of SOS, raf, and MEK by MAPK
(ERK) point to a possible feedback regulation. Further
feedback regulation is brought about by MAPK-in-
duced phosphorylation of protein tyrosine phosphatase
2C (PP2C) [52], resulting in decreased protein phos-
phatase activity and prolongation of tyrosine kinase
signal transduction. Here, another point of cross-talk
between serpentine-and growth factor receptors ex-
ists; activation of PKC leads to phosphorylation and
inactivation of protein tyrosine phosphatase PP2A
[53], suggesting that tyrosine  signaling can  be pro-
longed by activation of PKC.
Upon activation, MAPK also partly translocates to
the nucleus. There, several phosphorylation processes
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can occur that mediate transcriptional regulation. One
of the nuclear substrates for MAPK is p62TCF (ternary
complex factor, or Elk-1). Upon phosphorylation, ter-
nary complex formation between Elk-1, the serum re-
sponse factor (SRF), and the serum response element
(SRE) is stimulated, and in this way transcriptional
activity from target genes is enhanced. This is also a
diverging point for MAPK signaling; overexpression of
p44MAPK (ERK1) but not of p42MAPK (ERK2) led to acti-
vation of Elk-1 [54]. Other transcription factors that
are phosphorylated and activated are c-myc (by ERK2
and not by ERK1) and c-jun, together with RNA po-
lymerase II. The data above indicate that activation of
the MAPK pathway can stimulate protein and RNA
synthesis in general but can also lead to the activation
of speci~c genes, e.g., those containing the SRE.
Some observations directly implicate the MAPK
(ERK) pathway in the development of hypertrophy.
Microinjection of constitutively active ras in myocytes
is accompanied by morphological changes reminiscent
of hypertrophy and leads to increased ANF expression
[55]. Furthermore, transfection with constitutively ac-
tivated MEK increased the ANF promoter activity. In
this study, cotransfection with wild-type (wt)-ERK2
led to enhanced stimulation of this promoter [56] as
well as to activated b-MHC, skeletal a-actin, and c-fos
promoter. Other data with respect to the involvement
of the MAPK pathway in induction of hypertrophy by
serpentine receptor agonists will be discussed below.
Another member of the MAPK superfamily that is
present in cardiomyocytes is the stress-activated pro-
tein kinase (SAPK). Although this pathway is not acti-
vated by tyrosine kinase receptors, it might also be
involved, through as yet unidenti~ed cross-talk mecha-
nisms with, e.g., the hypertrophy-inducing AngII path-
way [57]. The SAP kinase, also known as JNK, i.e.,
c-jun NH2-terminal kinase, activates c-jun through
phosphorylation of amino-terminal serine residues.
However, upstream activation signals for SAPK acti-
vation have only received limited attention in cardiac
myocytes.
Cytokine receptors and the JAK/STAT pathway.
Receptors for the cytokine family all share a b-receptor
unit (gp130) in their signal transduction [58]. The
speci~c receptor for the hypertrophic cytokine-like
protein cardiotrophin-1 (CT-1) is the leukemia inhibi-
tory factor (LIF) receptor. Upon dimerization with the
cytokine-speci~c receptor complex (CT-1•LIF), gp130
transduces the cytokine signal to the cytoplasm. Al-
though gp130 does not harbor intrinsic tyrosine kinase
activity, dimerization leads to activation of gp130-asso-
ciated tyrosine kinases. These Janus-associated ki-
nases (JAKs), in their turn, directly phosphorylate and
activate the dormant cytoplasmic transcription factors
STAT (i.e., signal transducer and activator of transcrip-
tion) that, upon translocation to the nucleus, can ho-
modimerize or heterodimerize into sis-inducing factor
(SIF) complexes that regulate sis-inducing element
(SIE) containing target genes.
The signal transduction pathway initiated by cytok-
ine receptors can, as was the case for serpentine recep-
tors, cross-talk with the MAPK pathway. However, the
mechanism of this cross-talk is largely unclear and is
hypothesized to involve an adaptor protein that acti-
vates ras.
Agonist-speci~c signal transduction
Although it has been described that growth factor re-
ceptor-mediated signaling by IGF-I and bFGF induces
hypertrophy, no cardiomyocyte-speci~c details con-
cerning intracellular signal  transduction are  known.
Therefore,  only the  best-studied pathways—that  is,
those activated by AngII, ET-1, and the a1-adrenergic
agonist PHE—will be described. Additionally, recent
data about signaling through the LIF receptor that can
be activated by CT-1 will be described.
Angiotensin-II. AngII, through the AT1 receptor
and presumably through Gq, leads to activation of PLC
in cardiac myocytes. This activation, however, is very
transient, as re_ected in low levels of inositol phos-
phate production [2]. On the other hand, the intracellu-
lar [Ca21] was increased by AngII, suggesting that
locally increased InsP3 levels might release Ca21 from
intracellular stores [59,60]. Although an increase in 1,2-
DAG by AngII was reported in cardiac myocytes [2],
no data are available on PKC activation by AngII in
these cells. However, AT1 receptor-transfected COS
cells respond to AngII by increase in intracellular
[Ca21] as well as by activation of PKC-a and -e [61].
Stimulation of cardiomyocytes by AngII also results
in activation of the MAPK pathway; tyrosine kinase
activity increased, and p42MAPK and p44MAPK were
phosphorylated [60]. Downregulation of PKC by pre-
treatment with PMA did not suppress MAPK activa-
tion by AngII, suggesting that cross-talk between the
AngII-activated phosphoinositide and MAPK path-
ways is not brought about by PKC. On the other hand,
chelation of intracellular Ca21 completely inhibited the
activation of the MAPKs. The identity of the Ca21-
regulated adaptor proteins that mediate cross-talk be-
tween the  phosphoinositide  and MAPK pathway  is,
however, still unclear.
Endothelin-1. In cardiomyocytes, ET-1 activates
phospholipase C through Gq coupled to the ETA recep-
tor [32]. The InsP3 level is not increased, which is also
re_ected in a near absence of increase in intracellular
[Ca21] [46]. In contrast, 1,2-DAG levels are increased,
which results in the rapid translocation (activation) at
low [ET-1] of PKC-e, whereas PKC-d is translocated at
higher ET-1 concentrations [52]. Besides PLC, phos-
pholipase D is activated, giving rise to 1,2-DAG pro-
duction from phosphatidylcholine. It was shown that
activation of PKC with phorbolester PMA (a 1,2-DAG
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analogue) leads to PLD activation [62]. Therefore,
PLD activation   after ET-1 stimulation   might be
brought about by PKC and could represent a feedfor-
ward mechanism to prolong the supply of 1,2-DAG and
PKC activity [52].
Another G-protein that is activated by ET-1 is Gi.
As described above, this activation leads to a de-
creased PKA activity, possibly releasing b-adrenergic
inhibition of c-raf kinase and leading to sensitization of
the MAPK pathway.
In cardiac myocytes, stimulation with ET-1 also ac-
tivated the MAPK pathway [36,52]. The stimulation is
accompanied by raf (MAPKKK) activation that is at
least partly dependent on activation of PKC. Activa-
tion of PKA leads to decreased raf activation by ET-1
[52]. Therefore, cross-talk exists between ET-1-in-
duced raf activation (through Gq and Gi, as described
above) and b-adrenergic inhibition of raf through phos-
phorylation by PKA. Activation of raf is re_ected in
activation MEK (MAPKK) and subsequently ERK1
and ERK2. This MAPK activation is detectable within
~ve minutes and gradually declines to control values in
an hour. The mechanism by which ET-1 activates the
MAPK pathway may not only depend on the Ga
subunits described above. ET-1 stimulation also leads
to tyrosine phosphorylation of Shc (SH2-domain con-
taining protein). It was described that phosphorylation
of the abundant cytoplasmic adaptor protein Shc can
be mediated through Gbc subunits [63]. The Shc pro-
tein then might serve as an adaptor for Grb2 by which
SOS is activated, leading to ras activation as described
for tyrosine receptors (see above), but this pathway
has not been studied in cardiomyocytes.
Surprisingly, yet another MAPK superfamily is in-
volved in signaling by ET-1. It was shown that stimu-
lation of cardiac myocytes leads to activation of the
stress-activated JNK/SAPK pathway that, among oth-
ers, regulates c-jun activity [52]. However, no further
details about the involvement of this cascade in hyper-
trophy induction are available.
a1-adrenergic agonists. Activation of the a1-adren-
ergic receptor by phenylephrine was reported to lead
to activation of phospholipase C through Gq. InsP3 lev-
els are   not increased due to rapid phosphoryla-
tion/dephosphorylation reactions, re_ected in the ab-
sence of an increase in intracellular [Ca21], as was the
case for ET-1 [46]. This activation results in increased
1,2-DAG levels, and PKC-d and PKC-e are activated,
judged by translocation to the particulate fraction [45].
Coordinated  activation  of the  MAPK pathway  is
brought about by PHE, and this activation is partly
sensitive to PKC depletion [45,64]. On the other hand,
stimulation with PHE also resulted in a tyrosine ki-
nase-dependent activation of ras. This ~nding suggests
that crosstalk by PHE to the MAPK pathway is
brought about by PKC as well as by tyrosine kinase-
dependent signal transduction. The identity of the
adaptor that mediates tyrosine-dependent ras activa-
tion might again be Shc, as described above for ET-1,
but de~nite conclusions cannot yet be drawn.
Con_icting reports exist regarding the mechanism
by which ras and MAPK are involved in ANF expres-
sion and morphological changes related to hypertrophy
after a1-adrenergic stimulation. By transfection of a
dominant interfering ras mutant, it was shown that the
a1-adrenergic activation of MAPK and stimulation of
the ANF promoter was dependent on ras activation
[55]. In a second study, expression of dominant nega-
tive MAPKs interfered with activation of the promoter
by constitutively activated ras but failed to block a1-ad-
renergic stimulation of ANF promoter activity [65].
Furthermore, p24 and p44 MAPK activation by ATP or
carbachol did not induce ANF expression, and inhibi-
tion of MAPKs did not block PHE-stimulated ANF
promoter expression. This study thus suggests that
ras-induced MAPK-dependent and PHE-regulated
MAPK-independent pathways exist that regulate
ANF expression. In a third study, depletion of p42 and
p44 MAPK activity by antisense oligodeoxynu-
cleotides was reported to inhibit the development of
morphological features of hypertrophy as well as to
attenuate the induction of ANF by PHE [66]. This
implicates MAPK activity in all aspects of hypertrophy
development. In a fourth study, expression of dominant
negative MAPK led to inhibition of PHE-induced ANF
reporter gene expression but did not prevent PHE-in-
duced morphological changes [67]. Thus, de~nite con-
clusions with regard to the involvement of ras and/or
MAPK in the regulation of ANF gene expression and
development of hypertrophy await further study. On
the other hand, a recent report indicates that, besides
ras, a second small GTP-binding protein, rho, is in-
volved in regulation of ANF expression after PHE
stimulation [69]. Inhibition of rho attenuates a1-adren-
ergic stimulation of ANF expression but does not in-
terfere with ERK activation by PHE. This ~nding sug-
gests that independent pathways exist that regulate
ANF expression and MAPK activation after a1-adren-
ergic stimulation.
Cardiotrophin-1. Direct intracellular signaling by
CT-1 has not been described. However, it was reported
that CT-1 binds to the LIF receptor. Therefore, until
more data are presented on CT-1 signaling, we can take
LIF-induced signaling to be representative for CT-1 as
well. In cultured cardiac  myocytes,  LIF  stimulated
JAK  phosphorylation  within  ~ve  minutes. The sub-
strate for LIF, STAT, was also phosphorylated within
~ve minutes and was gradually dephosphorylated by
60 minutes. On the other hand, both ERK1 and ERK2
were activated. The increase in MAPK activity was
detectable within two minutes after LIF stimulation,
was maximal at ~ve minutes, and gradually decreased
thereafter. These results show that the LIF/CT-1 re-
ceptor is coupled to JAK/STAT as well as MAPK acti-
vation. However, a direct link between these pathways
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and hypertrophy induction by CT-1 has not yet been
provided.
The data described above certainly implicate cross-
talk between kinase cascades as an important aspect of
G-protein (and possibly cytokine) signal transduction
towards hypertrophy. At the same time, we must now
realize that a complete picture of signal transduction
has not been gained yet but certainly comprises di-
verse kinase pathways involving PKC, ras and rho, and
ERK and JNK/SAPK kinases as well as JAK/STAT.
Gene Expression Regulation by
Nuclear Signals
Regulation of gene transcription is brought about by
activation or inhibition of transcription factors (trans-
acting factors) that bind to DNA sequences (cis-acting
elements) in the promoter of target genes. Studies into
transcription from promoters of several cardiac genes,
such as myosin light-chain-2, a- and b-MHC, and ANF
genes, have revealed several cis-acting elements and
trans-acting factors that are involved in cardiac myo-
cyte-speci~c expression. However, relatively little at-
tention has been given to the role of cis-acting ele-
ments in gene regulation by the MAPK pathway
during hypertrophy.
Activation of the MAPK pathway seems to underlie
the common mechanism by which hypertrophic stimuli
transduce their signals to changes ion gene expression.
In this section, two modes of hypertrophy-associated
gene regulation by nuclear signals derived from activa-
tion of the MAPK pathway will be described, as well as
multifactorial regulation.
SRE/CArG-mediated regulation
Upon activation, MAPK translocates to the nucleus,
where several  phosphorylation processes occur that
mediate transcriptional regulation. Phosphorylation of
the nuclear target Elk 1 enhances ternary complex
formation between Elk-1, the serum response factor
(SRF), and the serum response element (SRE). In this
way, transcriptional activity from genes containing an
SRE is enhanced. The cis-acting SRE is also known as
CArG, and intact SRF is required for muscle-speci~c
activation of promoters through this CArG box. This
CArG element plays a role in muscle-speci~c expres-
sion of several contractile protein genes such as the
skeletal/cardiac a-actin-, a-myosin heavy-, and myosin
light-chain genes.
One of the earliest genes induced by hypertrophic
stimuli is the c-fos gene. In a very elegant study, using
in vivo gene transfer, the activity of the c-fos promoter
coupled to a reporter gene was studied under condi-
tions of ventricular pressure overload [70]. Wt-c-fos
promoter (356 bp) activity was activated 3–fold by two-
hour pressure overload. Deletion of the SRE from this
promoter resulted in a loss of pressure-induced c-fos-
reporter gene expression. The SRE alone was able to
confer  pressure responsiveness to the  minimal  pro-
moter, indicating that this element is necessary and
suf~cient for pressure response. A point mutation in
SRE that abolishes interaction with Elk-1 from the
SRF abolished the pressure overload response. Fur-
thermore, the SRE is also required (and suf~cient) for
the AngII-induced activation of the c-fos gene [31].
This funding suggests that MAPK (ERK1) activation
followed by Elk-1 phosphorylation and enhanced SRF
formation is the underlying mechanism for c-fos induc-
tion during (pressure-overload) induced hypertrophy.
TRE-mediated regulation
Besides upregulation of c-fos expression by MAPK ac-
tivation as described above, other transcription factors
are activated and/or induced during hypertrophy. It
was shown that MAPK activation leads to phosphory-
lation and activation of c-jun. Moreover, the JNK/
SAPK pathway (activated by, e.g., AngII and ET-1)
also leads to activation of c-jun. From the simultaneous
activation of c-fos and c-jun, we can predict that
upregulation will occur of genes (promoters) that con-
tain TPA responsive element (TRE) sequences. Cis-
acting TRE elements are stimulated by the TRE-bind-
ing transcription factor complex AP-1 (activator
protein-1) that consists of homodimers and heterodi-
mers of fos and jun proteins. One of the genes that
contains functional TRE elements is the ANF gene. It
was reported that overexpression of c-jun in atrial
cardiomyocytes in the presence of a human ANF re-
porter gene  resulted  in a dramatic increase in pro-
moter activity that was dependent on the TRE ele-
ment [71]. Surprisingly, overexpression of c-fos
resulted in inhibition of the ANF promoter. However,
the inhibitory activity of c-fos was located in the car-
boxy terminus of the protein, while conventional AP-1-
dependent activity is located elsewhere in the mole-
cule, suggesting dual regulation by c-fos through the
AP-1 as well as other cis-acting elements. In a later
study, it was in fact shown that a carboxy-terminal
deletion  mutant of  c-fos  could stimulate the  human
ANF promoter [72]. The stimulation of c-fos expres-
sion by MAPK (ERK-1) and c-jun activity by the
MAPK as well as the JNK/SAPK pathways again de-
picts a cross-talk mechanism in the regulation of gene
expression during hypertrophy where c-fos inhibits
the stimulatory action of c-jun on ANF expression.
Another example of transcription regulation during
hypertrophy is the ET-1 gene. This gene is activated
by AngII in an AP-1- (TRE-) dependent manner under
conditions where c-fos as well as c-jun expression is
increased [57]. A minimal TRE-repeat promoter was
shown in this study to confer the responsiveness to
AngII as well.
Multifactorial regulation
Several studies indicate that regulation of gene ex-
pression is brought about by an interplay between sev-
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eral genetic element/binding factors. One of the best-
studied hypertrophic stimuli in this respect is the a1-
adrenergic agonist PHE. As described above, signal
transduction proceeds through the MAPK pathway.
Minimal promoter elements that could confer a1-adren-
ergic hypertrophic upregulation were identi~ed for the
ANF, MLC-2, and skeletal a-actin promoters [73,74].
Besides other elements, all three promoters contained
an SRE/CArG element, suggesting involvement of
MAPK/Elk-1 signaling. Furthermore, ANF and MLC-
2 contained a TRE (AP-1-binding element). This shows
that upregulation of gene expression can involve SRE
as well as the TREs described above.
The data described above indicate that activation of
the Elk-1, c-fos, and c-jun by the MAPK is involved in
some of the aspects of gene regulation during hyper-
trophy. However, more studies will have to be per-
formed to delineate the full spectrum of transcription
factors involved, such as c-myc, the early growth re-
sponse gene EGR-1, and possibly unknown factors as
well.
Future Directions
It is now evident that induction of hypertrophy is of
multifactorial origin. Furthermore, a broad array of
kinase cascades can be activated by each agonist, and
crosstalk is more the rule than the exception. Although
signal transduction and gene expression regulation
have been the focus of research in past years, much
remains to be learned.
At the moment, relatively little information is avail-
able concerning regulation of transcription factor ac-
tivity that dictates the detrimental phenotypic
changes during hypertrophy. Identi~cation of the
(regulation of) factors that govern expression of, e.g.,
SERCA2, phospholamban, and the b-adrenergic recep-
tor during hypertrophy is now of utmost importance.
This will ultimately enable us to devise strategies to
intervene in the decompensatory changes that occur
after prolonged hypertrophy, with the ultimate goal of
prevention of heart failure.
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